|
1
|
Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux.
|
J Pharmacol Exp Ther
|
2003
|
1.93
|
|
2
|
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
|
J Pharmacol Exp Ther
|
2010
|
1.59
|
|
3
|
Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
|
J Pharmacol Exp Ther
|
2010
|
1.57
|
|
4
|
P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
|
J Pharmacol Exp Ther
|
2009
|
1.56
|
|
5
|
Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up.
|
Curr Pharm Des
|
2011
|
1.47
|
|
6
|
Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.
|
Expert Rev Mol Med
|
2011
|
1.42
|
|
7
|
Drug efflux transporters in the CNS.
|
Adv Drug Deliv Rev
|
2003
|
1.37
|
|
8
|
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives.
|
Pharm Res
|
2007
|
1.35
|
|
9
|
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
|
J Pharmacol Exp Ther
|
2012
|
1.26
|
|
10
|
Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.
|
J Pharmacol Exp Ther
|
2012
|
1.25
|
|
11
|
Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma.
|
Drug Metab Dispos
|
2012
|
1.19
|
|
12
|
Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85.
|
Pharm Res
|
2003
|
1.17
|
|
13
|
Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice.
|
Drug Metab Dispos
|
2012
|
1.13
|
|
14
|
Distribution kinetics of a micelle-forming block copolymer Pluronic P85.
|
J Control Release
|
2004
|
1.09
|
|
15
|
P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.
|
Drug Metab Dispos
|
2007
|
1.06
|
|
16
|
AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives.
|
J Clin Pharmacol
|
2007
|
1.01
|
|
17
|
Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.
|
Drug Metab Dispos
|
2008
|
1.00
|
|
18
|
Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier.
|
Pharm Res
|
2005
|
0.99
|
|
19
|
Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine.
|
Drug Metab Dispos
|
2007
|
0.97
|
|
20
|
Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis.
|
J Cereb Blood Flow Metab
|
2006
|
0.97
|
|
21
|
Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse.
|
Drug Metab Dispos
|
2008
|
0.96
|
|
22
|
Distribution of the novel antifolate pemetrexed to the brain.
|
J Pharmacol Exp Ther
|
2005
|
0.95
|
|
23
|
Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells.
|
J Pharmacol Exp Ther
|
2004
|
0.94
|
|
24
|
Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.
|
Mol Cancer Ther
|
2012
|
0.94
|
|
25
|
Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium.
|
Neuro Oncol
|
2004
|
0.92
|
|
26
|
Determination of cediranib in mouse plasma and brain tissue using high-performance liquid chromatography-mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2011
|
0.90
|
|
27
|
Development of a respirable, sustained release microcarrier for 5-fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles.
|
J Pharm Sci
|
2006
|
0.89
|
|
28
|
Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
|
J Pharmacol Exp Ther
|
2012
|
0.89
|
|
29
|
Brain distribution and bioavailability of elacridar after different routes of administration in the mouse.
|
Drug Metab Dispos
|
2012
|
0.89
|
|
30
|
Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.
|
Mol Pharm
|
2012
|
0.88
|
|
31
|
Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.
|
J Pharmacol Exp Ther
|
2013
|
0.88
|
|
32
|
Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors.
|
J Pharm Sci
|
2008
|
0.88
|
|
33
|
pH-Dependent transport of pemetrexed by breast cancer resistance protein.
|
Drug Metab Dispos
|
2011
|
0.87
|
|
34
|
Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
|
J Pharmacol Exp Ther
|
2013
|
0.86
|
|
35
|
OCT2 and MATE1 provide bidirectional agmatine transport.
|
Mol Pharm
|
2010
|
0.85
|
|
36
|
Mitoxantrone permeability in MDCKII cells is influenced by active influx transport.
|
Mol Pharm
|
2007
|
0.85
|
|
37
|
Utilizing transmembrane convection to enhance solute sampling and delivery by microdialysis: theory and in vitro validation.
|
J Memb Sci
|
2010
|
0.84
|
|
38
|
Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
|
Drug Metab Dispos
|
2013
|
0.84
|
|
39
|
Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.
|
J Pharm Sci
|
2013
|
0.84
|
|
40
|
Measurement of drug release from microcarriers by microdialysis.
|
J Pharm Sci
|
2005
|
0.84
|
|
41
|
Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.
|
Clin Genitourin Cancer
|
2012
|
0.81
|
|
42
|
Development of a respirable, sustained release microcarrier for 5-fluorouracil II: In vitro and in vivo optimization of lipid coated nanoparticles.
|
J Pharm Sci
|
2006
|
0.79
|
|
43
|
Organic cation uptake is enhanced in bcrp1-transfected MDCKII cells.
|
Mol Pharm
|
2010
|
0.79
|
|
44
|
Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.
|
J Pharm Sci
|
2009
|
0.77
|
|
45
|
Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases.
|
Melanoma Res
|
2015
|
0.77
|
|
46
|
Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens.
|
Breast Cancer Res Treat
|
2006
|
0.77
|
|
47
|
Separation methods that are capable of revealing blood-brain barrier permeability.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2003
|
0.75
|
|
48
|
Drug transport studies using quantitative microdialysis.
|
Methods Mol Med
|
2003
|
0.75
|
|
49
|
Cardiac responses to the intrapericardial delivery of metoprolol: targeted delivery compared to intravenous administration.
|
J Cardiovasc Transl Res
|
2011
|
0.75
|